Japan approves Sanofi’s subcutaneous Sarclisa for myeloma

Japan approves Sanofi’s subcutaneous Sarclisa for myeloma

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.